Repligen (RGEN) return on equity (ROE)

Return on equity · fiscal 2025
2.3%

Repligen (RGEN) earned a return on equity of 2.3% in fiscal 2025 (the year ended December 31, 2025). That is 3.6 percentage points higher than the -1.3% of fiscal 2024. Figures as of 17 Nov 2026, 21:32 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
2.3%
Change on fiscal 2024
+3.6 pts
Highest on record
19.1%fiscal 2013
Lowest on record
-6.1%fiscal 2010
Fiscal years on record
172010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Repligen return on equity (ROE), in more detail

Across the 17 fiscal years on record (2010–2025), the highest was 19.1% in fiscal 2013 and the lowest -6.1% in fiscal 2010. The fiscal 2025 figure is higher than in 38% of the 16 earlier fiscal years on record, whose median is 4.4%.

History · 17 fiscal years

Return on equity by fiscal year

Repligen return on equity (ROE), year by year

Repligen (RGEN) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
20252.3% 3.6 pts up
2024-1.3% 3.1 pts down
20231.8% 7.9 pts down
20229.7% 2.4 pts up
20217.3% 3.4 pts up
20203.9% 1.9 pts up
20192.0% 0.7 pts down
20182.7% 2.1 pts down
20174.8% 2.1 pts down
20166.9% 0.7 pts down
20157.6% 0.3 pts up
20147.3% 11.8 pts down
201319.1% 2.3 pts up
201216.8% 19.3 pts up
2011-2.4%—
2011-0.1% 6.1 pts up
2010-6.1%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Repligen and comparable companies
CompanyReturn on equityFiscal year
Kymera Therapeutics KYMR-19.7%2025
DaVita DVA773.1%2024
Halozyme Therapeutics HALO649.2%2025
Universal Health Services UHS20.5%2025
Repligen RGEN2.3%2025
Bio-Techne TECH8.6%2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on RGEN

Repligen, figure by figure

Repligen (RGEN) overview: price, valuation and scorecardAll health care companies by market value

Repligen return on equity (ROE): questions and answers

What is Repligen's return on equity?

Repligen (RGEN) earned a return on equity of 2.3% in fiscal 2025 (the year ended December 31, 2025). That is 3.6 percentage points higher than the -1.3% of fiscal 2024.

Is Repligen's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 38% of the 16 earlier fiscal years on record, whose median is 4.4%.

What are the highest and lowest return on equity figures on record for Repligen?

Across the 17 fiscal years on record (2010–2025), the highest was 19.1% in fiscal 2013 and the lowest -6.1% in fiscal 2010.

How is Repligen's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Repligen (RGEN) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/RGEN/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.